1-7 of 7
Jeroen J.W.M. Janssen, MD
Close
Sort by
Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Markus Pfirrmann, PhD, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD, Antonio Almeida, MD PhD, Jeroen J.W.M. Janssen, MD PhD, Jiri Mayer, MD, Kimmo Porkka, MD PhD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Stromberg, MD PhD, Marc G. Berger, MD PhD, Joana Diamond, PhD, Hans Ehrencrona, MD PhD, Veli Kairisto, Katerina Machova Polakova, Martin C. Müller, MD, Satu Mustjoki, MD PhD, Andreas Hochhaus, MD, Susanne Sauβele, MD, Henrik Hjorth-Hansen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 789.
https://doi.org/10.1182/blood.V128.22.789.789
Published: 2016
Journal Articles

Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Gunther Gastl, Prof., Dr., Zlatko Trajanoski, Prof. Dr., Frank Giles, MD MB, Andreas Hochhaus, MD, Simon Geisler, Dietmar Fuchs, Prof. Dr., Dominik Wolf, MD, Jeroen J.W.M. Janssen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1912.
https://doi.org/10.1182/blood.V128.22.1912.1912
Published: 2016
Journal Articles

CML Treatment in Dutch Hospitals with Low Patient Volumes Is Associated with a Substandard Quality of Molecular Response Monitoring

Inge G.P. Geelen, MD, Noortje Thielen, MD PhD, Jeroen J.W.M. Janssen, MD PhD, Tanja Roosma, Otto Visser, MD PhD, Jan J. Cornelissen, MD PhD, Peter E. Westerweel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1913.
https://doi.org/10.1182/blood.V128.22.1913.1913
Published: 2016
Journal Articles

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML.

Jeroen J.W.M. Janssen, MD, Wendy Deenik, Karlijn G.M. Smolders, Monique Terwijn, Angele Kelder, J. J. Cornelissen, Gerrit-Jan Schuurhuis, Gert J. Ossenkoppele
Journal: Blood
Blood (2009) 114 (22): 3245.
https://doi.org/10.1182/blood.V114.22.3245.3245
Published: 2009
Journal Articles

High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.

Martine E.D. Chamuleau, MD, Arjan A. Van de Loosdrecht, MD, PhD, Corine J. Hess, MD, Jeroen J.W.M. Janssen, MD, Adri Zevenbergen, Ruud Delwel, PhD, Peter J.M. Valk, PhD, Bob Lowenberg, MD, PhD, Gert J. Ossenkoppele, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4297.
https://doi.org/10.1182/blood.V110.11.4297.4297
Published: 2007
Journal Articles

Immunogenecity of CML-DC Is Maintained upon Imatinib Mesylate: Implication for Vaccination Regimens.

Theresia M. Westers, Jeroen J.W.M. Janssen, MD, Niels C.L. Snoijs, Arjan A. van de Loosdrecht, MD PhD, Gert J. Ossenkoppele, MD PhD
Journal: Blood
Blood (2004) 104 (11): 4666.
https://doi.org/10.1182/blood.V104.11.4666.4666
Published: 2004
Journal Articles

Conditioning Regimens in Stem Cell Transplantations Facilitate Homing by Increasing Bone Marrow SDF-1 through Induction of SDF-1 Gene Transcription.

Sonja Zweegman, MD, Jeroen J.W.M. Janssen, MD, Floortje L. Kessler, Adriana M.C. Mus, Jacob van den Born, PhD, Peter C. Huijgens, MD, PhD, Angelika M. Drager, PhD
Journal: Blood
Blood (2004) 104 (11): 4958.
https://doi.org/10.1182/blood.V104.11.4958.4958
Published: 2004